Panitumumab binds to EGFR inhibiting the binding of ligands for EGFR, resulting in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR. Recombinant, human IgG2 kappa monoclonal antibody.

6 mg/kg administered over 60 minutes as an intravenous infusion every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.

Indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following chemotherapy regimens containing fluoropyrimidine, oxaliplatin, and irinotecan.

Most common include skin rash, hypomagnesemia, paronychia, fatigue, abdominal pain, nausea and diarrhea. Serious toxicities include pulmonary fibrosis, severe dermatologic toxicity complicated by infectious sequelae and septic death, infusion reactions, abdominal pain, hypomagnesemia, nausea, vomiting, and constipation.

Prepare for potential severe infusion reaction during infusion.

Reduce infusion rate by 50% in patients experiencing a mild or moderate (grade 1 or 2) infusion reaction for the duration of that infusion.

Immediately and permanently discontinue infusion in patients experiencing severe (grade 3 or 4) infusion reaction.

Withhold or adjust dose for moderate to severe dermatologic toxicity.

Do not administer as an IV push or bolus.

Administer by an IV infusion pump using a low-protein-binding 0.2 micron or 0.22 micron in-line filter.